Private labs wait for govt go-ahead to launch coronavirus test kits

ICMR on Saturday said all hospitalised patients who have pneumonia or severe acute respiratory illness will be tested for Covid-19.

Private labs wait for govt go-ahead to launch coronavirus test kits
Sohini Das Mumbai
2 min read Last Updated : Mar 22 2020 | 12:07 AM IST
As the country’s apex medical research body has now revised testing guidelines for Covid-19 infections, the private sector diagnostic players said that they are ready with testing kits and the protocol. 

Multiple players said they are waiting for the final go-ahead from the government, including directives on pricing if any, to launch the diagnostic test kits. 

A Velumani, chairman of Thyrocare Technologies told Business Standard that the infrastructure was ready. 

“Our infrastructure is ready, the team is ready and the protocols are in place,” he said, adding that they were waiting for approvals from the government. 

Most leading diagnostic chains are importing the kits for testing and that would make the logistics also difficult. Mumbai-based Metropolis Healthcare, for example, has tested multiple kits and has zeroed in on one from Germany. 

Others like Delhi-based Dr Lal Pathlabs and SRL Diagnostics, a Fortis unit, are also waiting for official communication from the government before they can start testing. 

The Indian Council of Medical Research (ICMR) on Saturday said all hospitalised patients who have pneumonia or severe acute respiratory illness (SARI) will be tested for Covid-19. SARI patients would have high fever, cough and shortness of breath as major symptoms. 

ICMR has also noted that anyone who has come in contact with a Covid-19 positive person should also be tested even if they do not show any symptoms.  So far India was testing people who had recently travelled abroad and subsequently showed symptoms, and people who had come in contact with these people and showed symptoms of Covid-19 infection.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusPharma Companieshealthcare technologiesIndian healthcare

Next Story